Advertisement

International Ophthalmology

, Volume 38, Issue 5, pp 2247–2255 | Cite as

Advances in the management of thyroid eye diseases: An overview

  • Rashmi Kumari
  • Bhawesh Chandra Saha
Review
  • 515 Downloads

Abstract

Introduction

Thyroid eye disease (TED) remains a notorious ailment for both patients and the treating ophthalmologists. Recent years have witnessed considerable research in the immunopathogenic mechanism of TED that has resulted in an expansion and modification of the available management options.

Aim

Purpose of this review is to summarise the advances in the management of thyroid ophthalmopathy.

Material and method

A thorough literature search and of the past 10 years web search with words Thyroid ophthalmopathy, recent, advances.

Results

Recent VISA classification and new serum markers seem to have potential to give diagnostic as well as therapeutic guidance, gauge treatment response and even identify risk of disease progression. Majority of TED patients can be managed conservatively due to its self-limiting nature but if indicated, still steroids are the preferable medical therapy; however, there is an increasing consensus towards the use of parenteral form as compared to the oral one on account of greater efficacy with lesser side effects. Steroid sparing medications, for example, rituximab, infliximab, etanercept, adalimumab, teprotumumab, tocilizumab, tanshinone, are showing encouraging results and form an area of active research.

Conclusion

Radiation therapy remains as an adjunctive modality in active diseases as a nonmedical treatment for TED with some promising data. Surgical intervention may be required in vision threatening conditions or to counteract the sequel of inflammatory phase. Advances in surgical techniques like stereotactic image-guided balanced orbital decompression with endoscopic approach ensure meticulous dissection with minimal trauma.

Keywords

Thyroid ophthalmopathy Thyroid eye disease VISA 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Scott IU, Siatkowski MR (1999) Thyroid eye disease. Semin Ophthalmol 14(2):52–61CrossRefPubMedCentralGoogle Scholar
  2. 2.
    Wiersinga WM, Bartalena L (2002) Epidemiology and prevention of Graves’ ophthalmopathy. Thyroid 12(10):855–860CrossRefGoogle Scholar
  3. 3.
    Bartley GB et al (1996) Clinical features of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol 121(3):284–290CrossRefPubMedCentralGoogle Scholar
  4. 4.
    Bartalena L, Pinchera A, Marcocci C (2000) Management ofGraves’ ophthalmopathy: reality and perspectives. Endocr Rev 21(2):168–199PubMedPubMedCentralGoogle Scholar
  5. 5.
    Werner SC (1969) Classification of the eye changes of Graves’ disease. Am J Ophthalmol 68:646–648CrossRefPubMedCentralGoogle Scholar
  6. 6.
    Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R (1989) Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. Br J Ophthalmol 73:639–644CrossRefPubMedCentralGoogle Scholar
  7. 7.
    Bartalena L, Baldeschi L, Dickinson AJ (2008) Consensus statement of the European Group on Graves’ Orbitopathy (EUGOGO) on management of Graves’ orbitopathy. Thyroid 158(3):273–285Google Scholar
  8. 8.
    Dolman PJ, Rootman J (2006) VISA classification for graves orbitopathy. Ophthal Plast Reconstr Surg 22:319–324CrossRefGoogle Scholar
  9. 9.
    Stiebel-Kalish H, Robenshtok E, Gaton DD (2010) Pathophysiology of Graves’ ophthalmopathy. Pediatr Endocrinol Rev 7(Suppl. 2):178–181PubMedPubMedCentralGoogle Scholar
  10. 10.
    Noh JY et al (2000) Thyroid-stimulating antibody is related to Graves’ ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves’ disease. Thyroid 10(9):809–813CrossRefPubMedCentralGoogle Scholar
  11. 11.
    Goh SY et al (2004) Thyroid autoantibody profiles in ophthalmic dominant and thyroid dominant Graves’ disease differ and suggest ophthalmopathy is a multiantigenic disease. Clin Endocrinol (Oxf) 60(5):600–607CrossRefGoogle Scholar
  12. 12.
    Boboridis K, Perros P (2008) General management plan. In: Weirsinga WM, Kahaly GJ (eds) Graves’ ophthalmopathy: a multidisciplinary approach. Karger, Basel, pp 88–95Google Scholar
  13. 13.
    Dodds NI, Atcha AW, Birchall D, Jackson A (2009) Use of high-resolution MRI of the optic nerve in Graves’ ophthalmopathy. Br J Radiol 82(979):541–544CrossRefPubMedCentralGoogle Scholar
  14. 14.
    Regensburg NI, Wiersinga WM, Berendschot TT, Saeed P, Mourits MP (2011) Densities of orbital fat and extraocular muscles in graves orbitopathy patients and controls. Ophthal Plast Reconstr Surg 27(4):236–240CrossRefGoogle Scholar
  15. 15.
    Krassas KE, Dumas A, Pontikides N et al (1995) Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease. Clin Endocrinol (Oxf) 42:571–580CrossRefGoogle Scholar
  16. 16.
    Bartalena L (2002) Smoking and Graves’ disease. J Endocrinol Invest 25:42CrossRefGoogle Scholar
  17. 17.
    Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M et al (2011) European group on Graves’ orbitopathy. Selenium and the course of mild Graves’ orbitopathy. N Engl J Med 364:1920–1931CrossRefGoogle Scholar
  18. 18.
    Terwee CB, Prummel MF, Gerding MN, Kahaly GJ, Dekker FW, Wiersinga WM (2005) Measuring disease activity to predict therapeutic outcome in Graves’ ophthalmopathy. Clin Endocrinol (Oxf) 62:145–155CrossRefGoogle Scholar
  19. 19.
    Kahaly GJ, Pitz S, Hommel G, Dittmar M (2005) Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J Clin Endocrinol Metab 90:5234–5240CrossRefGoogle Scholar
  20. 20.
    Zang S, Ponto KA, Kahaly GJ (2011) Clinical review: intravenous glucocorticoids for Graves’ orbitopathy: Efficacy and morbidity. J Clin Endocrinol Metab 96:320–332CrossRefGoogle Scholar
  21. 21.
    Silkiss RZ, Reier A, Coleman M, Lauer SA (2010) Rituximab for thyroid eye disease. Ophthal Plast Reconstr Surg 26:310–314CrossRefPubMedCentralGoogle Scholar
  22. 22.
    Salvi M, Vannucchi G, Campi I, Beck-Peccoz P (2009) Rituximab in the treatment of thyroid eye disease: science fiction? Orbit 28:251–255CrossRefPubMedCentralGoogle Scholar
  23. 23.
    Khanna D, Chong KK, Afifiyan NF, Hwang CJ, Lee DK, Garneau HC et al (2010) Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology 117(133–139):e2Google Scholar
  24. 24.
    Salvi M, Vannucchi G, Campi I, Rossi S, Bonara P, Sbrozzi F et al (2006) Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur J Endocrinol 154:511–517CrossRefPubMedCentralGoogle Scholar
  25. 25.
    Stan MN, Garrity JA, Carranza Leon BG et al (2015) Randomized controlled trial of rituximab in patients with Graves’ orbitopathy. J Clin Endocrinol Metab 100:432–441CrossRefGoogle Scholar
  26. 26.
    Salvi M, Vannucchi G, Campi I, Currò N, Beck-Peccoz P (2008) New immunomodulators in the treatment of Graves’ ophthalmopathy. Ann Endocrinol (Paris) 69:153–156CrossRefGoogle Scholar
  27. 27.
    Komorowski J, Jankiewicz-Wika J, Siejka A, Lawnicka H, Klysik A, Gos R et al (2007) Monoclonal anti-TNFalpha antibody (infliximab) in the treatment of patient with thyroid associated ophthalmopathy. Klin Oczna 109:457–460PubMedPubMedCentralGoogle Scholar
  28. 28.
    Ayabe R, Rootman DB, Hwang CJ et al (2014) Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease. Ophthal Plast Reconstr Surg 30:415–419CrossRefPubMedCentralGoogle Scholar
  29. 29.
    Chen H, Mester T, Raychaudhuri N et al (2014) Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes. J Clin Endocrinol Metab 99:E1635–E1640CrossRefPubMedCentralGoogle Scholar
  30. 30.
    Pérez-Moreiras JV, Alvarez-López A, Gómez EC (2014) Treatment of active corticosteroid-resistant graves’ orbitopathy. Ophthal Plast Reconstr Surg 30:162–167CrossRefPubMedCentralGoogle Scholar
  31. 31.
    Rhiu S, Chae MK, Lee EJ et al (2014) Effect of tanshinone IIA in an in vitro model of Graves’ orbitopathy. Invest Ophthalmol Vis Sci 55:5900–5910CrossRefPubMedCentralGoogle Scholar
  32. 32.
    Bartalena L, Marcocci C, Tanda ML, Rocchi R, Mazzi B, Barbesino G et al (2002) Orbital radiotherapy for Graves’ ophthalmopathy. Thyroid 12:245–250CrossRefPubMedCentralGoogle Scholar
  33. 33.
    Viebahn M, Barricks ME, Osterloh MD (1991) Synergism between diabetic and radiation retinopathy: case report and review. Br J Ophthalmol 75:629–632CrossRefPubMedCentralGoogle Scholar
  34. 34.
    Robertson DM, Buettner H, Gorman CA, Garrity JA, Fatourechi V, Bahn RS et al (2003) Retinal microvascular abnormalities in patients treated with external radiation for graves ophthalmopathy. Arch Ophthalmol 121:652–657CrossRefPubMedCentralGoogle Scholar
  35. 35.
    Wu CH, Chang TC, Liao SL (2008) Results and predictability of fat-removal orbital decompression for disfiguring Graves’ exophthalmos in an Asian patient population. Am J Ophthalmol 145:755–759CrossRefPubMedCentralGoogle Scholar
  36. 36.
    Bleier BS, Lefebvre DR, Freitag SK (2014) Endoscopic orbital floor decompression with preservation of the inferomedial strut. Int Forum Allergy Rhinol 4:82–84CrossRefPubMedCentralGoogle Scholar
  37. 37.
    Baril C, Pouliot D, Molgat Y (2014) Optic neuropathy in thyroid eye disease: results of the balanced decompression technique. Can J Ophthalmol 49:162–166CrossRefPubMedCentralGoogle Scholar
  38. 38.
    Bingham CM, Harris MA, Vidor IA et al (2014) Transcranial orbital decompression for progressive compressive optic neuropathy after 3-wall decompression in severe Graves’ orbitopathy. Ophthal Plast Reconstr Surg 30:215–218CrossRefPubMedCentralGoogle Scholar
  39. 39.
    Servat JJ, Elia MD, Gong D et al (2014) Electromagnetic image-guided orbital decompression: technique, principles, and preliminary experience with 6 consecutive cases. Orbit 33:433–436CrossRefPubMedCentralGoogle Scholar
  40. 40.
    Garrity JA, Saggau DD, Gorman CA et al (1992) Torsional diplopia after transantral orbital decompression and extraocular muscle surgery associated with Graves’ orbitopathy. Am J Ophthalmol 113:363–373CrossRefPubMedCentralGoogle Scholar
  41. 41.
    Mills MD, Coats DK, Donahue SP, Wheeler DT (2004) Strabismus surgery for adults: a report by the American Academy of Ophthalmology. Ophthalmology 111:1255–1262CrossRefPubMedCentralGoogle Scholar
  42. 42.
    Ribeiro SFT, Garcia DM, Leal V et al (2014) Graded Müllerectomy for correction of Graves’ upper eyelid retraction. Ophthal Plast Reconstr Surg 30:384–387CrossRefPubMedCentralGoogle Scholar
  43. 43.
    Kohn JC, Rootman DB, Liu W et al (2014) Hyaluronic acid gel injection for upper eyelid retraction in thyroid eye disease. Ophthal Plast Reconstr Surg 30:400–404CrossRefPubMedCentralGoogle Scholar
  44. 44.
    Elshafei AMK, Abdelrahman RM (2014) Gold weight implants for management of thyroid-related upper eyelid retraction. Ophthal Plast Reconstr Surg 30:427–430CrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2017

Authors and Affiliations

  1. 1.Regional Institute of OphthalmologyIGIMSPatnaIndia
  2. 2.Department of EyeAIIMSPatnaIndia

Personalised recommendations